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Direct medical costs were estimated using tariffs for laboratory tests, diagnostic 
exams, visits, and prices for drugs. Procedure and inpatient cost data were collected 
at Center level. Non medical costs included costs for travel and accommodation, 
domestic help and informal care. The loss of productivity of patients have been 
estimated using the human capital approach. The incremental effects of having 
comorbidities on social costs were estimated by multivariate Generalized Linear 
Models (log link, Gamma family) adjusting for gender, age, BMI, type of interven-
tion and complications. Costs are expressed in Euro 2013. Results: Among 301 
patients enrolled, 108 (36%) had hypertension, 53 (18%) T2DM and 47 (16%) ADD. The 
raw social cost of intervention were € 8,749 (± € 2,359), € 9,511 (± € 2,292) and € 8,999 
(± € 2,275) for patients with hypertension, T2DM and ADD. A significant incremen-
tal effect of having T2DM was found on social cost of intervention (€ 751, 95%CI: 
242-1,259, p= 0.004). 1 year after intervention reductions of 48%, 81% and 15% were 
observed for hypertension, T2DM and ADD. The raw social annual costs estimated 
were € 2,461 (± € 1,490) for hypertension, € 2,424 (± € 951) for T2DM and € 3,582 (± 
€ 2,017) for ADD. Direct non medical costs and indirect costs represent the main 
component of social cost in patients with hypertension and ADD. ConClusions: 
Bariatric surgery led to reductions of obesity-related comorbidities. One year after, 
the economic burden is mainly sustained by patients, their families and the pro-
ductivity system.
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objeCtives: The objective of this study is to estimate the average annual direct 
and indirect costs associated with Duchenne muscular dystrophy (DMD) in Italy 
considering both National Health System (NHS) societal perspective. Methods: 
A probabilistic prevalence-based cost of illness model was used to estimate the 
economic impact of a rare disease as DMD. All the costs were determined through 
a survey that families registered with the Muscular Dystrophy Association “Parent 
Project onlus” completed on-line. NHS and family prospective has been analyzed 
dividing the patients into three age groups (< 8, 8 – 16 and > 16). Human capital 
approach was used to determine loss of productivity due to absenteeism, while the 
bottom up approach was used to calculate direct costs. Furthermore, a probabilistic 
sensitivity analysis with 5,000 Monte Carlo simulations was performed, in order 
to test the robustness of results and define the 95%CI. Results: Indirect costs 
are those that weigh more on the total expenditure of the NHS with € 474.634.836 
(95%CI: € 300.028.168 - € 698.965.090) per year, while the direct health care costs are € 
7.475.596 (95%CI: € 5.124.369,29 - € 10.263.785) and nonmedical costs are € 12.944.879 
(95% CI: € 7.925.699 - € 19.175.331). Patients with more than 16 years spend more 
than those between 0 and 7 years old, and even more than those between 8 and 15. 
For what concern the private expenditure, the model estimated € 2.910.506 (95%CI: 
€ 345.231,83 - € 718.786) for the direct costs, and € 185.333.744 (95%CI: € 114.177.282 
- € 273.446.219) for the nonmedical costs. ConClusions: Although DMD is a rare 
disease, its economic impact on NHS is quite remarkable. Furthermore, the most 
of the impact relies on families and society.
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objeCtives: To estimate the burden of myelofibrosis (MF) in Greece, focusing on 
epidemiological data, quality of life (QoL), direct and indirect costs. Methods: A 
17-page questionnaire was developed, validated, and completed with the Delphi 
technique. It included questions on epidemiological, resource use, QoL and socio-
economic data. An expert panel with 9 KOL haematologists was convened consisting 
of experts from the largest Haematology Units of Greece, covering geographically 
six out of seven Regional Health Authorities. Unit costs in 2014 prices were taken 
from officially published sources. The societal perspective was adopted. Results: 
Prevalence and incidence rates of MF in Greece are approx. 2.5: 100,000 and 0.7: 
100,000 people respectively, corresponding to approx. 270 patients (71.7% with pri-
mary and 28.3% with secondary) and 76 new cases every year; 92% of the patients 
present with splenomegaly at diagnosis, 1/3 of which reduce their daily activi-
ties. Current treatment options in Greece are ruxolitinib and best supportive care 
(BSC). 72.6% of the primary and 65% of the secondary MF patients treated with 
ruxolitinib show improvement of splenomegaly vs. 23% and 7%, respectively for 
patients treated with BSC. Ruxolitinib patients show QoL improvement and less 
splenectomies (< 1%) compared with BSC patients (~3%). Work loss days associated 
with ruxolitinib are estimated at 23 days per year (51 days for BSC), and 20% of them 
return to work after treatment (5% for BSC). The annual direct cost of managing 
all MF patients in Greece is estimated at € 1.65 million, including pharmaceuti-
cal, hospital, follow-up costs, blood transfusions, and management of infections. 
Productivity losses are estimated at € 217,975 per year, resulting in a total annual 
burden of approx. € 1.87 million. ConClusions: MF is associated with significant 
burden to patients, their families, and to the society. Treatment with ruxolitinib 
appears to improve patients’ QoL and reduce indirect costs, mainly through reduc-
tion of splenomegaly and splenectomies.
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and costs (all p< 0.05), the adjusted annual incremental costs in abusers versus non-
abusers were $28,882 (95% Confidence Interval [CI]: $28,455-$29,311) and $15,523 
(95% CI: $15,389-$15,657) per patient among Medicaid and commercially insured 
patients, respectively, during the post-index period. The main cost driver was inpa-
tient hospitalization which comprised 88% of unadjusted incremental costs during 
follow up in Medicaid insured population and 53% in commercial insured popula-
tion. ConClusions: Diagnosed opioid abusers among long-term IR hydrocodone 
users impose significantly higher financial burden in both Medicaid and commer-
cially insured populations in terms of all-cause direct health care expenditures, 
ranging from $28,882 to $15,523 per abuser per year.
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objeCtives: Although acromegaly is acknowledged as requiring resource-intensive 
treatment, its ultimate economic burden is unclear. As an extension of work pre-
sented at ISPOR 2013 International Conference (New Orleans, US), the objective of 
this research is to measure the annual economic burden of acromegaly in Italy using 
a case-review methodology with a prevalence-based sample of patients diagnosed 
with acromegaly. Methods: A case-review method was used with a sample of 22 
endocrinologists reviewing 86 patient cases (4 cases per physician) diagnosed with 
acromegaly. The patient case histories included: resource utilization including office 
visits and hospitalization, diagnostic procedures and labs, medications prescribed, 
medical procedures preformed, and an estimate of lost productivity. A micro-costing 
analysis was conducted to obtain costs in the prior 12 months for each patient case 
reviewed, using published literature, medical fee schedules, and pharmaceutical 
cost databases to assign costs to treatments and medical procedures identified in 
the survey data. Annual costs were examined across a broad range of patients of 
different ages, gender and time from diagnosis. Two biomarkers were used to cat-
egorize acromegaly patients as Controlled vs. Uncontrolled: Insulin Growth Factor-1 
(IGF-1) and Growth Hormone (GH). Several patient characteristics were used as 
control factors when comparing annual economic impact: age, sex, and time from 
diagnosis. Statistical tests and confidence intervals were calculated to determine the 
significance of patient characteristic effects on economic burden. Results: Three 
patient subgroups were used to classify uncontrolled acromegaly patients: IGF-1, 
GH and both IGF-1 and GH. The annual per-patient economic burden of disease 
costs ranges from € 18,600 to € 38,000 across these groups. These cost ranges are 
benchmarked to other studies to provide context and validity. ConClusions: The 
total economic burden acromegaly in Italy is significant. Understanding the factors 
impacting burden of illness will inform future improvements in treatment practice.
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objeCtives: The aim of this study was to assess the indirect costs caused by absen-
teeism associated with psoriatic and enteropathic arthropathies from the perspec-
tive of the Social Insurance Institution (ZUS) in Poland. Methods: The estimates 
were based on data published by ZUS referring to year 2012 and concerning absence 
from work due to the illness (sick leave), the amount of short term disability, the 
sufferers of which claim rehabilitation benefit, and the amount of permanent (or 
long term) disability, the sufferers of which claim disability pension. Costs were 
calculated with Human Capital Approach methodology taking into account Gross 
Domestic Product (GDP) per capita equaled 41 398 PLN; results were presented 
in Polish zloty (PLN). Results: Total indirect costs of psoriatic and enteropathic 
arthropathies in the year 2012 calculated using GDP per capita in Poland were 9 
312 773 PLN. The highest component of indirect costs of psoriatic and enteropathic 
arthropathies was sick leave (82%). Long and short term disability costs consti-
tute 9% and 8% of total indirect costs of psoriatic and enteropathic arthropathies, 
respectively. In 2012 Poland’s Social Insurance Institution database reported 1 900 
patients on sick leave, 54 patients with short term disability and 3 patients with 
long term disability. Indirect costs per patient associated with sick leave were 4 
037 PLN calculated using GDP per capita. Indirect costs per patient associated with 
short term disability were as high as 16 227 PLN and associated with long term 
disability were as high as 255 288 PLN. ConClusions: Psoriatic and enteropathic 
arthropathies in Poland generated high indirect costs. The main component was 
sick leave; rehabilitation benefit and disability pension generated much lower costs 
of lost productivity.
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objeCtives: To estimate the social cost of bariatric surgery techniques in obese 
patients with hypertension, diabetes mellitus (T2DM) and anxiety-depression disor-
ders (ADD). Methods: A longitudinal multicenter study was conducted by enroll-
ing obese adult patients in charge to 6 Hospital in Italy at time of intervention of 
gastric banding, gastric by-pass, and sleeve gastrectomy and following up to 1 year. 
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objeCtives: Systemic Lupus Erythematosus (SLE) is an autoimmune disease, char-
acterized by periods of remissions and flares, with significant clinical and economic 
burden. The primary study objective was to estimate the 1-year direct medical cost 
for adult patients with active, autoantibody-positive SLE in Greece. Methods: This 
is a national, multi-centre, retrospective study. Data were abstracted from patient 
records in 6 hospital centers specialized in SLE management. Starting with the 
patient with the most recent visit, patients with consecutive visits (backwards in 
time) were considered for inclusion, provided they met specific criteria. In order to 
estimate costs per disease severity, a stratification criterion was applied. Patient 
data were collected for a 1-year period starting from the inclusion date (January 
-September 2011) and moving forward. Data included patient characteristics and 
health care resource utilization. In addition, all SLE patients fulfilling the inclu-
sion criteria and followed-up in the participating centers during a 3-month ret-
rospective period were recorded. For cost calculation, official 2013 list prices were 
used. Results: 215 patients (30% severe according to the stratification criterion) 
were included in the study. Mean direct medical costs were estimated at € 1,225 
for patients with non-severe and at € 3,741 for patients with severe active SLE. 
Laboratory and imaging tests, medicines, physicians’ visits, and hospitalization 
costs represented 10.5%, 51.7%, 1.2%, 36.5% of mean cost respectively. Costs were 
statistically significantly higher for severe SLE patients. The total number of patients 
visiting the participating clinical sites during a 3-month period was 318 (19% with 
severe SLE). The weighted mean annual direct medical cost of SLE in Greece was esti-
mated at € 1,703. ConClusions: Direct medical cost of SLE in Greece is significant, 
especially for patients with severe disease. An estimation of indirect costs would 
provide a comprehensive picture of the societal burden of the disease.
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objeCtives: Immune thrombocytopenia (ITP) is characterized by isolated thrombo-
cytopenia with no underlying cause. It manifests clinically as mucocutaneous bleed-
ing caused by decreased platelets. Recently, two thrombopoietin receptor-agonists 
have emerged as an important therapeutic options: romiplostim and eltrombopag. 
Since these medications have different mode of administration, safety and effi-
cacy profiles, the present study was carried out in an attempt to investigate which 
drug would be more cost-effective in the Brazilian setting. The objective was to 
perform an economic analysis evaluating the cost per response of romiplostim 
versus eltrombopag in adult patients with chronic ITP and refractory to other treat-
ments as corticosteroids and immunoglobulins in Brazil health care private sys-
tem. Methods: Two economic analyses were performed in order to study the use 
of romiplostim and eltrombopag for the treatment of adults with chronic refractory 
ITP, based on annual treatment costs and cost per response. The average body weight 
adopted was 74,6 kg. Efficacy data were obtained from the product inserts, as well 
as from scientific publications. In cost per response, it was considered a 6-month 
analysis, which corresponds to the overall platelet response in clinical trials. The 
outcome of these trials was the global response to treatment. The cost of each drug 
presentation were based on ex-factory price (VAT 18%) and obtained from the official 
price list (CMED; April, 2014). Results: The cost of treatment with romiplostim 
showed an annual saving of R$7,724 over eltrombopag within the payer perspec-
tive, which may be further improved if we assume that drug-food interactions of 
eltrombopag in some patients lead to reduced medication adherence and loss of 
response. The cost per response with romiplostim was 26% lower than with eltrom-
bopag. ConClusions: Romiplostim was more cost-effective than eltrombopag for 
the treatment of chronic refractory ITP in adult patients and may represent savings 
to the Brazilian health system.
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objeCtives: This study evaluated the impact of BMI category on health utilities, 
health care resource-utilisation, productivity, activity impairment, and associated 
costs. Methods: Results were from the 2013 EU5 National Health and Wellness 
Survey (N= 62,000), a nationally representative, online survey of respondents 
aged ≥ 18 years. This analysis focused on normal weight (BMI≥ 18.5 & < 25 kg/m2), 
overweight (BMI≥ 25 & < 30 kg/m2), obese class (OC) I (BMI≥ 30 & < 35 kg/m2), OC II 
(BMI≥ 35 & < 40 kg/m2), and OC III (BMI≥ 40 kg/m2) respondents. Patients provided 
information on SF-6D (health utility) scores, productivity loss (Work Productivity and 
Activity Impairment questionnaire) and resource-utilisation (type/number of visits) 
in the past six months. Direct and indirect costs were estimated from the literature. 
Generalised linear models predicted resource use and productivity as a function of 
BMI category, adjusting for covariates (e. g., age, gender, comorbidities). Results: 
Among 58,364 respondents, 46.9% were normal weight, 34.5% were overweight, 
12.5% were OC I, 4.0% were OC II, and 2.1% were OC III. Metabolic comorbidities 
increased as BMI increased. Adjusting for covariates, health utility (normal weight: 
0.720; overweight: 0.718; OC I: 0.703; OC II: 0.683; OC III: 0.662) scores declined with 
an increase in BMI (all p< 0.05 vs. normal). Among employed patients (57.7%), overall 
work impairment increased as BMI increased (normal weight: 17.9%; overweight: 
18.4%; OC I: 19.0%; OC II: 21.4%; OC III: 26.7%, p< 0.05 all OCs vs. normal). Normal 
objeCtives: The aim of this study was to assess the indirect costs associated with 
multiple sclerosis (MS) from the perspective of Social Insurance Institution (ZUS) 
in Poland. Methods: The estimates were based on data from the Social Insurance 
Institution (ZUS) referring to year 2012 and focused on absenteeism due to the 
illness: costs of sick leave as well as the short-term disability due to rehabilitation 
benefit and the burden of permanent (or long term) disability due to disability pen-
sion in Poland. Cost analysis was performed based on the Human Capital Approach 
taking into account Gross Domestic Product (GDP) per capita equaled 41 398 PLN 
and Gross Value Added (GVA) per worker equaled 99 697 PLN. Costs were presented 
in polish zloty (PLN). Results: Total indirect costs of multiple sclerosis associ-
ated with absenteeism in the year 2012 in Poland were 39 870 385 PLN calculated 
using GDP per capita and 96 018 323 PLN as a GVA per worker. The predominant 
component of absenteeism of MS was sick leave, which accounted for 69%. Long 
and short term disability costs constituted 21% and 9% of total indirect costs of 
multiple sclerosis associated with absenteeism, respectively. One sick leave of 
person with multiple sclerosis generated the cost of lost productivity equal 1 866 
PLN and 4 490 PLN calculated using GDP per capita and GVA per worker, respec-
tively. Indirect cost of short-term disability for one entitlement to the benefit of 
rehabilitation were 17 077 PLN and 41 125 PLN, respectively. Cost of one long term 
benefit were much higher than short term benefit and equaled 41 398 PLN and 99 
697 PLN, respectively. ConClusions: Multiple sclerosis in Poland generated very 
high indirect costs. The main component was sick leave; disability pension and 
rehabilitation benefit generated lower costs of lost productivity.
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objeCtives: The aim of this study was to assess the indirect costs caused by absen-
teeism associated with ankylosing spondylitis (AS) from the perspective of the Social 
Insurance Institution (ZUS) in Poland. Methods: The estimates were based on data 
provided by ZUS referring to year 2012 and concerning absence from work due to 
the illness (sick leave), the amount of short term disability, the sufferers of which 
claim rehabilitation benefit, and the amount of permanent (or long term) disability, 
the sufferers of which claim disability pension. Costs were calculated with Human 
Capital Approach methodology taking into account Gross Domestic Product (GDP) 
per capita equaled 41 398PLN and Gross Value Added (GVA) per worker equaled 99 
697PLN and were presented in 2012 prices in Polish zloty (PLN). Results: Total 
indirect costs of AS in the year 2012 calculated using GDP per capita and GVA per 
worker in Poland were 21 299 578PLN and 51 294 959PLN, respectively. The high-
est component of indirect costs of AS was sick leave (56%). Long and short term 
disability costs constitute 6% and 39% of total indirect costs of AS, respectively. In 
2012 Poland’s Social Insurance Institution database reported 3 500 patients on sick 
leave, 72 patients with short term disability and 7 patients with long term disability. 
Indirect costs per patient associated with sick leave were 3 400PLN and 8 188PLN 
calculated using GDP per capita and GVA per worker, respectively. Indirect costs 
per patient associated with short term disability were 16 602PLN and 39 983PLN 
respectively and associated with long term disability were as high as 1 171 958PLN 
and 2 822 381PLN, respectively. ConClusions: AS in Poland generated high indirect 
costs. The main component was sick leave; rehabilitation benefit and disability 
pension generated lower costs of lost productivity.
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objeCtives: To assess the direct and indirect costs of systemic lupus erythema-
tosus (SLE), analysis of which is complex due to the heterogeneity of the disease, 
accumulative organ damage and associated comorbidities. Methods: Direct and 
indirect costs attributable to SLE were extracted from studies published January 
2004–March 2013, identified using Medline, EMBASE, EconLit and NHS EED. Eligible 
studies involved adults with active SLE. Results: The direct cost associated with 
SLE management was € 3,691/yr in Europe.1 In the US, annual health care costs 
were $10,984 higher for SLE patients vs non-SLE controls.2 Organ damage and 
disease activity were key drivers of annual cost variations;1–4 in Europe, cardio-
vascular/respiratory (€ 596/yr) and renal involvement (€ 511/yr) appeared the most 
costly organs.1 Estimated direct annual cost of treating any flare in the EU was 
~€ 399, whilst for severe flares was ~€ 1,002.1 In the US, renal involvement was the 
most costly organ: cost ratios were 3.1 (95% CI: 2.3–4.2) in newly diagnosed and 2.7 
(95% CI: 2.4–3.0) in existing SLE patients.4 Annual costs for mild and severe flares 
in the US were $129/flare and $11,716/flare, respectively.2 The indirect economic 
burden is also substantial, as SLE typically occurs during the peak of working 
years and in young women with child-bearing potential (around the age of 20 in 
Black females and 30 in White females).5,6 Predictors of future work loss in SLE 
included older age, shorter job tenure, thrombotic and musculoskeletal manifes-
tations, greater number of manifestations and high disease.7,8 ConClusions: 
The direct and indirect economic burden is prominent within SLE patients. Organ 
damage is a substantial “hidden cost” and should be considered when assessing 
the economic impact 
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